# Effects of Ocrevus in Relapsing Multiple Sclerosis

> **NCT04387734** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Georgia State University** · enrollment: 60 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** Ocrelizumab
- **DRUG:** Platform

## Key facts

- **NCT ID:** NCT04387734
- **Lead sponsor:** Georgia State University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-05
- **Primary completion:** 2025-02-17
- **Final completion:** 2026-04-30
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04387734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04387734, "Effects of Ocrevus in Relapsing Multiple Sclerosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04387734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*